345 related articles for article (PubMed ID: 21558016)
21. Current issues in dendritic cell cancer immunotherapy.
López JA; Hart DN
Curr Opin Mol Ther; 2002 Feb; 4(1):54-63. PubMed ID: 11885565
[TBL] [Abstract][Full Text] [Related]
22. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
23. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
Foley R; Tozer R; Wan Y
Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell vaccines for cancer treatment.
Gabrilovich DI
Curr Opin Mol Ther; 2002 Oct; 4(5):452-8. PubMed ID: 12435046
[TBL] [Abstract][Full Text] [Related]
25. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M
Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
[TBL] [Abstract][Full Text] [Related]
27. Harnessing dendritic cells in cancer.
Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
[TBL] [Abstract][Full Text] [Related]
28. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell immunotherapy.
Sabado RL; Bhardwaj N
Ann N Y Acad Sci; 2013 May; 1284():31-45. PubMed ID: 23651191
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
31. Poxviruses as vectors for cancer immunotherapy.
Kwak H; Hörig H; Kaufman HL
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
[TBL] [Abstract][Full Text] [Related]
32. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells and cancer immunotherapy.
Radford KJ; Tullett KM; Lahoud MH
Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
[TBL] [Abstract][Full Text] [Related]
34. Cancer vaccines for established cancer: how to make them better?
Andrews DM; Maraskovsky E; Smyth MJ
Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
[TBL] [Abstract][Full Text] [Related]
35. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
36. Roadmap to a better therapeutic tumor vaccine.
Emens LA
Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782
[TBL] [Abstract][Full Text] [Related]
37. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
38. Migration of dendritic cell based cancer vaccines: in vivo veritas?
Adema GJ; de Vries IJ; Punt CJ; Figdor CG
Curr Opin Immunol; 2005 Apr; 17(2):170-4. PubMed ID: 15766677
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell immunotherapy: mapping the way.
Figdor CG; de Vries IJ; Lesterhuis WJ; Melief CJ
Nat Med; 2004 May; 10(5):475-80. PubMed ID: 15122249
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
